These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 30530630)

  • 1. Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation.
    Lao JP; DiPrimio N; Prangley M; Sam FS; Mast JD; Perlstein EO
    G3 (Bethesda); 2019 Feb; 9(2):413-423. PubMed ID: 30530630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
    Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
    Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A frequent mild mutation in ALG6 may exacerbate the clinical severity of patients with congenital disorder of glycosylation Ia (CDG-Ia) caused by phosphomannomutase deficiency.
    Westphal V; Kjaergaard S; Schollen E; Martens K; Grunewald S; Schwartz M; Matthijs G; Freeze HH
    Hum Mol Genet; 2002 Mar; 11(5):599-604. PubMed ID: 11875054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolutionary rescue of phosphomannomutase deficiency in yeast models of human disease.
    Vignogna RC; Allocca M; Monticelli M; Norris JW; Steet R; Perlstein EO; Andreotti G; Lang GI
    Elife; 2022 Oct; 11():. PubMed ID: 36214454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Analysis of Variants in the General Population Reveals That
    Citro V; Cimmaruta C; Monticelli M; Riccio G; Hay Mele B; Cubellis MV; Andreotti G
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations.
    Vega AI; Pérez-Cerdá C; Abia D; Gámez A; Briones P; Artuch R; Desviat LR; Ugarte M; Pérez B
    J Inherit Metab Dis; 2011 Aug; 34(4):929-39. PubMed ID: 21541725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypes and estimated prevalence of phosphomannomutase 2 deficiency in Turkey differ significantly from those in Europe.
    Yıldız Y; Arslan M; Çelik G; Kasapkara ÇS; Ceylaner S; Dursun A; Sivri HS; Coşkun T; Tokatlı A
    Am J Med Genet A; 2020 Apr; 182(4):705-712. PubMed ID: 31981409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of PMM2-CDG-Causing Mutations on the Folding, Activity, and Stability of the PMM2 Protein.
    Yuste-Checa P; Gámez A; Brasil S; Desviat LR; Ugarte M; Pérez-Cerdá C; Pérez B
    Hum Mutat; 2015 Sep; 36(9):851-60. PubMed ID: 26014514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2.
    Chan B; Clasquin M; Smolen GA; Histen G; Powe J; Chen Y; Lin Z; Lu C; Liu Y; Cang Y; Yan Z; Xia Y; Thompson R; Singleton C; Dorsch M; Silverman L; Su SM; Freeze HH; Jin S
    Hum Mol Genet; 2016 Jun; 25(11):2182-2193. PubMed ID: 27053713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.
    Schiff M; Roda C; Monin ML; Arion A; Barth M; Bednarek N; Bidet M; Bloch C; Boddaert N; Borgel D; Brassier A; Brice A; Bruneel A; Buissonnière R; Chabrol B; Chevalier MC; Cormier-Daire V; De Barace C; De Maistre E; De Saint-Martin A; Dorison N; Drouin-Garraud V; Dupré T; Echenne B; Edery P; Feillet F; Fontan I; Francannet C; Labarthe F; Gitiaux C; Héron D; Hully M; Lamoureux S; Martin-Coignard D; Mignot C; Morin G; Pascreau T; Pincemaille O; Polak M; Roubertie A; Thauvin-Robinet C; Toutain A; Viot G; Vuillaumier-Barrot S; Seta N; De Lonlay P
    J Med Genet; 2017 Dec; 54(12):843-851. PubMed ID: 28954837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Chaperoning: A Potential Treatment for PMM2-CDG.
    Yuste-Checa P; Brasil S; Gámez A; Underhaug J; Desviat LR; Ugarte M; Pérez-Cerdá C; Martinez A; Pérez B
    Hum Mutat; 2017 Feb; 38(2):160-168. PubMed ID: 27774737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypolipidaemia among patients with PMM2-CDG is associated with low circulating PCSK9 levels: a case report followed by observational and experimental studies.
    Chong M; Yoon G; Susan-Resiga D; Chamberland A; Cheillan D; Paré G; Seidah NG
    J Med Genet; 2020 Jan; 57(1):11-17. PubMed ID: 31391289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG).
    Thiesler CT; Cajic S; Hoffmann D; Thiel C; van Diepen L; Hennig R; Sgodda M; Weiβmann R; Reichl U; Steinemann D; Diekmann U; Huber NM; Oberbeck A; Cantz T; Kuss AW; Körner C; Schambach A; Rapp E; Buettner FF
    Mol Cell Proteomics; 2016 Apr; 15(4):1435-52. PubMed ID: 26785728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional significance of PMM2 mutations in mildly affected patients with congenital disorders of glycosylation Ia.
    Westphal V; Peterson S; Patterson M; Tournay A; Blumenthal A; Treacy EP; Freeze HH
    Genet Med; 2001; 3(6):393-8. PubMed ID: 11715002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A zebrafish model of PMM2-CDG reveals altered neurogenesis and a substrate-accumulation mechanism for N-linked glycosylation deficiency.
    Cline A; Gao N; Flanagan-Steet H; Sharma V; Rosa S; Sonon R; Azadi P; Sadler KC; Freeze HH; Lehrman MA; Steet R
    Mol Biol Cell; 2012 Nov; 23(21):4175-87. PubMed ID: 22956764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary ovarian insufficiency in a female with phosphomannomutase-2 gene (PMM2) mutations for congenital disorder of glycosylation.
    Masunaga Y; Mochizuki M; Kadoya M; Wada Y; Okamoto N; Fukami M; Kato F; Saitsu H; Ogata T
    Endocr J; 2021 May; 68(5):605-611. PubMed ID: 33583911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PMM2-CDG: phenotype and genotype in four affected family members.
    Bortot B; Cosentini D; Faletra F; Biffi S; De Martino E; Carrozzi M; Severini GM
    Gene; 2013 Dec; 531(2):506-9. PubMed ID: 23988505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new insight into PMM2 mutations in the French population.
    Le Bizec C; Vuillaumier-Barrot S; Barnier A; Dupré T; Durand G; Seta N
    Hum Mutat; 2005 May; 25(5):504-5. PubMed ID: 15844218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterodimerization of Two Pathological Mutants Enhances the Activity of Human Phosphomannomutase2.
    Andreotti G; Monti MC; Citro V; Cubellis MV
    PLoS One; 2015; 10(10):e0139882. PubMed ID: 26488408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal involvement in PMM2-CDG, a mini-review.
    Altassan R; Witters P; Saifudeen Z; Quelhas D; Jaeken J; Levtchenko E; Cassiman D; Morava E
    Mol Genet Metab; 2018 Mar; 123(3):292-296. PubMed ID: 29229467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.